Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404417 | 0.82 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL13404363 | 0.78 | ALDH1A1 (0.58) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL13404356 | 0.77 | ALDH1A1 (0.57) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL13742881 | 0.77 | ALDH1A1 (0.54) | L3MBTL1ALDH1A1TSHRLMNAGAA | |
| SCHEMBL13743129 | 0.75 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1TSHRKMT2AGAA | |
| SCHEMBL13404373 | 0.75 | TSHR (0.51) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL3596115 | 0.73 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL13742871 | 0.71 | GAA (0.65) | ALDH1A1TSHRLMNAGAAMAPT | |
| SCHEMBL13743077 | 0.71 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL13671936 | 0.70 | CNR1 (0.85) | L3MBTL1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | L3MBTL1 4729/4885ALDH1A1 3117/4885TSHR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.